A Phase 3 interventional study of Pneumovax™ 23 in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections — 1 open to participants now, 1 under way, 1 of them phase 3. 23-valent pneumococcal capsular polysaccharide vaccine · Pneumococcal Infections.
Among the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, this one is the 13th largest by enrollment, is the only one that started in 2013, is one of 6 in phase 3, and was the 5th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Sites in China
Ages 2+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 2 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2013.
This study's enrollment of 102 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 243 across the 15 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 41st largest by enrollment, is the only one that started in 2013, is one of 31 in phase 3, and was the 8th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing 23-valent pneumococcal capsular polysaccharide vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Pneumovax™ 23 (V110) is safe and immunogenic in participants from the Russian population who are 50 years of age and older or 2 to 49 years of age and at increased risk for pneumococcal disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
Biological: Pneumovax™ 23
Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
Biological: Pneumovax™ 23
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
Also known as: V110
Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine
Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays
Time frame: Prevaccination and Day 28 after vaccination
Percentage of Participants With >=2-fold Increase From Prevaccination to Postvaccination in Antibodies to Pneumococcal Serotypes Contained in the Vaccine
Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. A \>=2-fold increase in serum antibody is a marker for serologic response to pneumococcal vaccination in adults.
Time frame: Day 28 postvaccination
Number of Participants With Elevated Body Temperature (>=37.6 °C Axillary / >=38.0 °C Oral or Equivalent)
Time frame: Up to 5 days postvaccination
Number of Participants Reporting an Injection-site or Systemic Adverse Experience That Was Reported by >=4 Participants
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. Injection-site or systemic AEs that occurred in \>=4 participants were reported for this endpoint.
Time frame: Up to Day 14 postvaccination
Number of Participants Reporting Serious Adverse Experiences
A serious AE (SAE) is an AE that 1) results in death, 2) is life threatening, 3) results in a persistent or significant disability or incapacity, 4) results in or prolongs an existing inpatient hospitalization, 5) is a congenital anomaly or birth defect, 6) is a cancer, 7) is an overdose, or 8) is another important medical event which, based on appropriate medical judgment, may jeopardize the participant and may require medical or surgical intervention
Time frame: Up to Day 28 postvaccination
| Milestone | Pneumovax™ 23: Participants Between 2 and 49 Years | Pneumovax™ 23: Participants >=50 Years |
|---|---|---|
| Started | 52 | 50 |
| Completed | 52 | 50 |
| Not completed | 0 | 0 |
Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays
| ug/mL | Pneumovax™ 23: Participants Between 2 and 49 Years | Pneumovax™ 23: Participants >=50 Years |
|---|---|---|
| Serotype 1 prevaccination | 0.2 (0.2 to 0.3) | 0.2 (0.2 to 0.3) |
| Serotype 1 Day 28 postvaccination | 4.1 (3.0 to 5.4) | 2.5 (1.7 to 3.8) |
| Serotype 6B prevaccination | 0.5 (0.4 to 0.8) | 0.6 (0.5 to 0.8) |
| Serotype 6B Day 28 postvaccination | 2.7 (1.8 to 3.9) | 5.3 (3.4 to 8.5) |
| Serotype 14 prevaccination | 1.3 (0.8 to 2.0) | 3.6 (2.5 to 5.1) |
| Serotype 14 Day 28 postvaccination | 13.2 (8.7 to 20.1) | 32.7 (22.7 to 47.3) |
| Serotype 19F prevaccination | 1.5 (1.1 to 2.2) | 1.5 (1.1 to 2.1) |
| Serotype 19F Day 28 postvaccination | 12.6 (9.0 to 17.8) | 9.9 (7.0 to 14.1) |
| Serotype 23F prevaccination | 0.6 (0.4 to 1.0) | 1.1 (0.7 to 1.5) |
| Serotype 23F Day 28 postvaccination | 5.3 (3.6 to 7.7) | 8.1 (5.3 to 12.4) |
Serum antibodies to pneumococcal serotypes were measured by enzyme-linked immunosorbent assays. A \>=2-fold increase in serum antibody is a marker for serologic response to pneumococcal vaccination in adults.
| Percentage of participants | Pneumovax™ 23: Participants Between 2 and 49 Years | Pneumovax™ 23: Participants >=50 Years |
|---|---|---|
| Serotype 1 | 96.2 (86.8 to 99.5) | 87.5 (74.8 to 95.3) |
| Serotype 6B | 76.9 (63.2 to 87.5) | 89.6 (77.3 to 96.5) |
| Serotype 14 | 88.5 (76.6 to 95.6) | 89.6 (77.3 to 96.5) |
| Serotype 19F | 82.7 (69.7 to 91.8) | 79.2 (65.0 to 89.5) |
| Serotype 23F | 80.8 (67.5 to 90.4) | 87.5 (74.8 to 95.3) |
| Number of participants | Pneumovax™ 23: Participants Between 2 and 49 Years | Pneumovax™ 23: Participants >=50 Years |
|---|---|---|
| Number of Participants With Elevated Body Temperature (>=37.6 °C Axillary / >=38.0 °C Oral or Equivalent) | 1 | 0 |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the sponsor's product, is also an AE. Injection-site or systemic AEs that occurred in \>=4 participants were reported for this endpoint.
| Number of participants | Pneumovax™ 23: Participants Between 2 and 49 Years | Pneumovax™ 23: Participants >=50 Years |
|---|---|---|
| Number of Participants Reporting an Injection-site or Systemic Adverse Experience That Was Reported by >=4 Participants | 16 | 5 |
A serious AE (SAE) is an AE that 1) results in death, 2) is life threatening, 3) results in a persistent or significant disability or incapacity, 4) results in or prolongs an existing inpatient hospitalization, 5) is a congenital anomaly or birth defect, 6) is a cancer, 7) is an overdose, or 8) is another important medical event which, based on appropriate medical judgment, may jeopardize the participant and may require medical or surgical intervention
| Number of participants | Pneumovax™ 23: Participants Between 2 and 49 Years | Pneumovax™ 23: Participants >=50 Years |
|---|---|---|
| Number of Participants Reporting Serious Adverse Experiences | 0 | 0 |
Collected over All adverse experiences were collected through Day 14 postvaccination; serious adverse experiences were collected through Day 28 postvaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pneumovax™ 23 | — | 0/102 (0%) | 14/102 (13.7%) |
| Event | Pneumovax™ 23 |
|---|---|
| Injection site painGeneral disorders | 14/102 |
| Age, Continuous(Years) | Pneumovax™ 23: Participants Between 2 and 49 Years | Pneumovax™ 23: Participants >=50 Years | Total |
|---|---|---|---|
| Mean | 21.2 ± 15.3 | 60.4 ± 7.7 | 40.4 ± 23.1 |
| Sex: Female, Male(Participants) | Pneumovax™ 23: Participants Between 2 and 49 Years | Pneumovax™ 23: Participants >=50 Years | Total |
|---|---|---|---|
| Female | 16 | 21 | 37 |
| Male | 36 | 29 | 65 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2013 to primary completion in Oct 2013, 4 months.
Results were first posted in Sep 2014, 10 months after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 4 months is below that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine